Business
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260%
About this update from Alvotech
[{"type":"text","content":"Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first quarter of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on March 8, 2025, at 8:00 am ET (12:00 pm GMT). “Alvotech maintains its strong momentum, with positive cash flows from operating activities in the first quarter and healthy product margins, driven by new launches and increasing manufacturing efficiencies. In 2025 Alvotech expects to be free cash-flow positive, and I’m pleased to note that the business is self-funded going forward. Based on strong response to our acquisition of all rights to the proposed biosimilar to Cimzia and to the broadening of our development pipeline, we are increasing full year guidance, to $600-$700 million in top-line revenue and $200-$280 million in adjusted EBITDA,” said Robert Wessman, Chairman and CEO of Alvotech. “Launching four new biosimilars remain key near-term priorities. With the acquisition of Xbrane’s operations and expansion of our R&D activity into Sweden we continue building one of the most valuable pipelines in the industry and leveraging our investment in a unique vertically integrated platform for biosimilars development and manufacturing.” Business Highlights in Q1 2025 Alvotech and its U.S. commercial partner Teva Pharmaceutical announced the launch of SELARSDI™ (ustekinumab-aekn) biosimilar to Stelara®, in the U.S. SE...